Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

ClinicalTrials.gov ID: NCT02635672

Public ClinicalTrials.gov record NCT02635672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of VIP152 (BAY 1251152) as Monotherapy or Combination Therapy in Subjects With Advanced Cancer.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive non-hodgkin's lymphoma (NHL).

Study identification

NCT ID: NCT02635672
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Vincerx Pharma, Inc.; Industry
Enrollment: 110 participants

Conditions and interventions

Conditions

Neoplasms

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 10, 2016 (Actual)
Primary completion: Nov 11, 2024 (Actual)
Completion: Nov 11, 2024 (Actual)
Last update posted: Nov 15, 2024

2016 – 2024

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Highlands Oncology Group	Springdale	Arkansas	72762	—
Norton Cancer Institute	Louisville	Kentucky	40202	—
Maryland Oncology Hematology	Silver Spring	Maryland	20904	—
John Theurer Cancer Center	Hackensack	New Jersey	07601	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
University of Cincinnati Medical Center	Cincinnati	Ohio	45219	—
Willamette Valley Cancer Institute	Eugene	Oregon	97401	—
Oregon Health and Science University	Portland	Oregon	97239	—
Avera Health	Sioux Falls	South Dakota	57105	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
NEXT Oncology	Austin	Texas	78758	—
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	—
NEXT Oncology	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02635672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 15, 2024 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02635672 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →